Pediatric Hematology/Oncology and Immunopathology

Treatment of acute myeloblastic leukemia in children by the AML MM 2000 protocol: Preliminary results of cooperative Russian–Belarus studies

Authors / Institutions

Litvinko N.P. / Republican Center of Pediatric Oncology and Hematology, Minsk, Republic of Belarus

Shneider M.M. / Federal Scientific and Clinical Center of Children’s Hematology, Oncology and Immunology, Ministry of Public Health and Social Development of the Russian Federation, Moscow

Savva N.N. / Republican Center of Pediatric Oncology and Hematology, Minsk, Belarus Republic

O.V.Aleinikova / Republican Center of Pediatric Oncology, Hematology, and Immunology, Minsk, Belarus Republic

Mareiko Yu.E. / Republican Center of Pediatric Oncology, Hematology, and Immunology, Minsk, Belarus Republic

Strongin Yu.S. / Republican Center of Pediatric Oncology and Hematology, Minsk, Republic of Belarus

Stasevich I.V. / Republican Center of Pediatric Oncology and Hematology, Minsk, Republic of Belarus

Yutskevich R.I. / Republican Center of Pediatric Oncology and Hematology, Minsk, Republic of Belarus

Kustanovich A.M. / Republican Center of Pediatric Oncology and Hematology, Minsk, Republic of Belarus

Zharikova L.I. / Federal Scientific and Clinical Center of Children’s Hematology, Oncology and Immunology, Ministry of Public Health and Social Development of the Russian Federation, Moscow

D.D.Baidildina / Russian Pediatric Clinical Hospital, Moscow / Federal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry Rogachev, Moscow, Russian Federation

E.V.Suntsova / Russian Pediatric Clinical Hospital, Moscow / Federal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry Rogachev, Moscow, Russian Federation

L.A.Khachatryan / Dmitry Rogachev Federal Research Center of Paediatric Haematology, Oncology, and Immunology, Moscow, Russian Federation

M.A.Maschan / Dmitry Rogachev Federal Research Center of Paediatric Haematology, Oncology, and Immunology, Moscow, Russian Federation

Skorobogatova E.V. /
Dyshlevaya Z.M. / Federal Scientific and Clinical Center of Children’s Hematology, Oncology and Immunology, Ministry of Public Health and Social Development of the Russian Federation, Moscow

D.V.Litvinov / Dmitry Rogachev Federal Research Center of Paediatric Haematology, Oncology, and Immunology, Moscow, Russian Federation

Fleishman E.V. / Institute of Carcinogenesis, Moscow

Nasedkina T.V. / V.A.Engelgardt Institute of Molecular Biology, Moscow

E.A.Isaeva / I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation

A.A.Maschan / Dmitry Rogachev Federal Research Center of Paediatric Haematology, Oncology, and Immunology, Moscow, Russian Federation

A.G.Rumyantsev / Dmitri Rogachev Federal Scientific and Clinical Centre of Paediatric Haematology, Oncology and Immunology, Ministry of Health of the Russian Federation, Moscow, Russian Federation

23 <-hr>- <-A name=2>-<-/a>-Н.П. Литвинко, М.М. Шнейдер, Н.Н. Савва, О.В. Алейникова и др. Intermediate results of treatment of children with first diagnosed acute myeloblastic leukemia (AML) by the AML MM 2000 pro tocol in Russia and Belarus are presented. The study was carried out in 116 children, mean age 10.7 years (3 weeks to 18 years 8 months). Clinical hematological remission has been attained in 103 (88.8%) patients, of these 48 (46.6%) children are in the first lasting remission (FLR). Five year overall survival (OS), event free survival (EFS), and relapse free survival (RFS) for the entire group of patients were 0.42±0.05, 0.38±0.05, and 0.52±0.05, respectively. The favorable prognosis group consisted of 30 patients, of these clinical hematological remission was attained in 29 (96.7%)- no disease resistance cases were observed- early death ensued in 1 (3.3%) patient- relapses developed in 8 (27.6%) patients, 4 (13.8%) died in remission, and 17 (58.6%) were in FLR. Five year OS was 0.70±0.08, EFS 0.53±0.09, and RFS 0.64±0.09. The unfavorable prognosis group consisted of 86 patients, of these clinical hematological remission was attained in 74 (86%) children, disease resistance was observed in 4 (4.7%), early death ensued in 8 (9.3%) children, 32 (43.2% children developed relapses, 8 (10.8%) children died in remission, and  31 (41.9%) children were in FLR. Five year OS was 0.34±0.05, EFS 0.33±0.05, and RFS 0.47±0.06. Allogenic transplantation of hemopoietic stem cells (THSC) from relatives was carried out in 11 patients of the unfavorable prognosis group. Mortality asso ciated with allogenic THSC was 18.2% (2 patients), 4 year RFS being 1.0±0.0. Autologous THSC was carried out in 42 patients of the unfavorable prognosis group. Mortality caused by autologous THSC was 9.5% (4 patients), relapses developed in  19 (45.2%) children, 5 year RFS was 0.43±0.08. Treatment by the AML MM 2000 protocol led to satisfactory results in the favor able prognosis group. The study showed high efficiency of allogenic THSC for RFS and the need in revision of approaches to autol ogous THSC in the treatment of AML.


Яндекс.Метрика